Lymphadenectomy in endometrial cancer

The Lancet

Volumn 373, Issue 9670, 2009, Pages 1170-

  Uccella, Stefano ^a   Podratz, Karl C ^a   Aletti, Giovanni D ^a   Mariani, Andrea ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GRADING; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; ENDOMETRIUM CANCER; HUMAN; LETTER; LYMPHADENECTOMY; PRIORITY JOURNAL; ENDOMETRIUM TUMOR; FEMALE; METHODOLOGY; NOTE; PATHOLOGY; PATIENT SELECTION; PELVIS; RISK FACTOR;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; PATIENT SELECTION; PELVIS; RESEARCH DESIGN; RISK FACTORS;

EID: 63349083194     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60677-2     Document Type: Letter

References (3)

1. The writing committee on behalf of the ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 (2009) 125-136
2. Mariani A., Dowdy S.C., Cliby W.A., et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109 (2008) 11-18
3. Mariani A., Dowdy S.C., Keeney G.L., Long H.J., Lesnick T.G., and Podratz K.C. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 95 (2004) 120-126